Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: diabetes + safety + efficacy  Related to the article below (Last Update: 7/1/2008)

pSivida Announces Interim Results From The Three-Month Readout Of ...
Medical News Today (press release), UK -
The study is secondarily designed to provide information on the safety and efficacy of Medidur in a DME population. A total of 37 subjects were enrolled in ...PSDVV - ASX:PVA
New Medicare Analysis Reinforces Safety, Efficacy of DES
Medscape (subscription) - Jun 26, 2008
However, among patients with diabetes, sirolimus-eluting stents were associated with better survival vs bare-metal stents. Randomized trials may be ...
AtheroGenics Receives Notice of Non-Compliance With Listing ...
CNNMoney.com -
These risks include: additional information relating to the safety, efficacy or tolerability of AGI-1067 may be discovered upon further analysis of trial ...AGIX
Alkermes Initiates Phase 3 Clinical Study Of VIVITROL(R) For The ...
Medical News Today (press release), UK -
The multi-center study is designed to assess the efficacy and safety of VIVITROL in approximately 200 patients diagnosed with opioid dependence. ...ALKS

ChattahBox
ADA: No Efficacy or Safety Sacrifice with Weekly Exenatide (Byetta)
MedPage Today, NJ - Jun 11, 2008
... MedPage Today SAN FRANCISCO, June 8 -- A long-acting version of the injectable diabetes drug exenatide (Byetta) showed efficacy advantages and safety ...
Novo Nordisk's Daring Success Motley Fool
Amylin gets a boost as latest drug weighs in San Diego Union Tribune
Amylin and Novo Nordisk Battle For GLP-1 Market Dominance TMCnet
PR Newswire (press release) - Earthtimes (press release)
all 200 news articles »  AMLN - LLY - ALKS
The Politics of Healthcare Rationing
istockAnalyst.com, OR - Jun 29, 2008
As The Wall Street Journal ?Diabetes Drugs Face Tougher Rules? points out, the FDA is only interested in safety and efficacy. Republicans want to ration ...
Alimera Reports Results From the Three-Month Interim Readout of ...
FOXBusiness - Jun 26, 2008
Secondarily, the study is designed to provide information on the safety and efficacy of Iluvien in a DME population. A total of 37 subjects were enrolled in ...
Abbott's Phase III Sub-Group Analysis Shows Investigational ...
FOXBusiness - Jun 8, 2008
These studies, along with a 52-week long-term safety and efficacy open-label extension study of 1911 patients, represent the largest program to date ...ABT - OTC:CMTX
Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide ...
WELT ONLINE, Germany - Jun 9, 2008
... with Type 2 Diabetes Mellitus (T2DM) Treated with Metformin: A Double-Blind Placebo-Controlled Phase 2 Study1 Study evaluated the efficacy, safety and ...
PREVIEW-Takeda new diabetes drug seen good but not great
Reuters - Jun 4, 2008
... prompting most Tokyo-based analysts to tentatively pronounce alogliptin to be roughly the same as Januvia in terms of safety and efficacy. ...TYO:4502
Source: Google News

… With Type 2 Diabetes Results of the Assessment of Diabetes Control and Evaluation of the Efficacy … -
SM Grundy, GL Vega, ME McGovern, BR Tulloch, DM … - Archives of Internal Medicine, 2002 - Am Med Assoc
... The Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial
(ADVENT) was therefore conducted to evaluate the safety and efficacy of low ...

Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in … -
PA Hollander, L Blonde, R Rowe, AE Mehta, JL … - Diabetes Care, 2004 - Am Diabetes Assoc
... Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous
Insulin Therapy in Patients With Type 2 Diabetes. Results ...

… counterpulsation for the relief of angina in patients with diabetes: safety, efficacy and 1-year … -
G Linnemeier, MK Rutter, G Barsness, ED Kennard, … - American Heart Journal, 2003 - Elsevier
... Clinical investigations. Enhanced external counterpulsation for the relief of angina
in patients with diabetes: safety, efficacy and 1-year clinical outcomes *1 ...

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European … -
TR Pieber, I Eugene-Jolchine, E Derobert - Diabetes Care, 2000 - ncbi.nlm.nih.gov
Click here to read Efficacy and safety of HOE 901 versus NPH insulin in patients
with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. ...

Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment … -
E Chantelau, M Spraul, I M?hlhauser, R Gause, M … - Diabetologia, 1989 - Springer
... of intensive supervision in determining the efficacy of insulin ... Diabetes Care
9:666-668 (Editorial) 54 ... Home PD, Marshall SM (1984) Problems and safety of continu ...

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin … -
B Charbonnel, A Karasik, J Liu, M Wu, G Meininger - Diabetes Care, 2006 - Am Diabetes Assoc
... page, JAMA Home page RE Amori, J. Lau, and AG Pittas Efficacy and Safety of Incretin
Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis JAMA, July ...

… and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. -
RF Coniff, JA Shapiro, TB Seaton, BJ Hoogwerf, JA … - Diabetes Care, 1995 - ncbi.nlm.nih.gov
A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose
for the treatment of patients with insulin-requiring type II diabetes. ...

Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. -
DE Kelley, P Bidot, Z Freedman, B Haag, D Podlecki … - Diabetes Care, 1998 - ncbi.nlm.nih.gov
Diabetes Care. 1998 Dec;21(12):2056-61. Click here to read Efficacy and safety
of acarbose in insulin-treated patients with type 2 diabetes. ...

Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor … -
TJ Wieman, JM Smiell, Y Su - Diabetes Care, 1998 - Mass Med Soc
... Citation(s): Wieman TJ et al. Efficacy and safety of a topical ... Diabetes Care 1998
May 21 822-827. Medline abstract (Free). Search. Enter keywords Advanced. ...

Efficacy, Safety, and Pump Compatibility of Insulin Aspart Used in Continuous Subcutaneous Insulin … -
BW Bode, P Strange - Diabetes Care, 2001 - Am Diabetes Assoc
... Efficacy, Safety, and Pump Compatibility of Insulin Aspart Used in Continuous
Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes. ...

Source: Google Scholar
 
 

Exubera's long-term efficacy and safety in adults with type 1 or type 2 diabetes

 
 
Results from two ongoing studies showed adults with type 1 or type 2 diabetes treated with Exubera, a rapid-acting, dry powder human Insulin, experienced sustained blood glucose control over a two-year period and gained about half as much weight as those taking injected Insulin.


Type 2 diabetes study

A total of 635 adults with type 2 diabetes who had stable injected Insulin therapy at baseline were randomized to receive either Exubera or continued injected insulin therapy.

Blood glucose levels ( A1c ) at baseline were 7.7 percent ( Exubera ) and 7.8 percent ( injected insulin ).
After two years of treatment, patients in both groups had similar improvement or maintained their blood glucose levels ( A1C levels of 7.3 percent ).
Patients with Exubera also achieved slightly better fasting blood glucose levels.

Weight gain in patients taking Exubera was 1.7 kg ( 3.7 pounds ) compared to 3 kg ( 6.6 pounds ) in patients taking injected Insulin.
<
Exubera was well-tolerated and this study confirmed that mean decreases in lung function relative to comparator treatments were small, occurred early, did not progress and showed resolution shortly after discontinuation of therapy.

Adverse events were similar in both groups with exception of cough, which was more frequent in the Exubera group.
The cough was defined as mild, occurring shortly after dosing and rarely resulted in discontinued treatment.


Type 1 diabetes study

A total of 582 adults with type 1 diabetes who had stable injected Insulin therapy at baseline were randomized to receive either Exubera or continued injected insulin therapy.

Baseline blood glucose levels ( A1c ) were 7.4 percent ( Exubera ) and 7.5 percent ( injected Insulin ). After two years of treatment, patients improved or maintained their blood glucose control.

Weight gain in patients taking Exubera was 0.8 kg ( 1.7 pounds ) compared to 2 kg ( 4.4 pounds ) in patients taking injected Insulin.

Exubera was well-tolerated, with comparable lung function changes, and this study confirmed that mean decreases in lung function relative to comparator treatments were small, occurred early and did not progress.

Adverse events were similar in both groups with the exception of cough, which was more frequent in the Exubera group. The cough was defined as mild, occurring shortly after dosing and rarely resulted in discontinued treatment.


Exubera is the first inhaled form of insulin and the first insulin option in the U.S., European Union in more than 80 years that does not need to be administered by injection.

It is a rapid-acting Insulin that is inhaled through the mouth prior to eating, using the handheld Exubera Inhaler. The unique Exubera Inhaler produces a standing cloud of Insulin powder, which is designed to pass rapidly into the bloodstream to regulate the body’s blood glucose levels.

In the U.S., Exubera is approved for the treatment of adults with type 1 or type 2 diabetes for the control of high blood glucose levels. In patients with type 2 diabetes, Exubera can be used alone or in combination with diabetes pills or longer-acting Insulin.
In patients with type 1 diabetes, Exubera should be used in combination with a longer-acting Insulin.

In the European Union, Exubera is approved for the treatment of adult patients with type 2 diabetes who require Insulin therapy and are not adequately controlled with diabetes pills. In patients with type 1 diabetes, Exubera should be used in combination with long or intermediate acting insulin.

Patients should not take Exubera if they have poorly controlled or unstable lung disease, or if they smoke or have stopped smoking less than six months prior to starting Exubera treatment. If a patient starts smoking or resumes smoking, he or she must stop using Exubera and see a health care provider about a different treatment.

Before starting treatment with Exubera, a health care provider will carry out a simple test to check lung function. This will help to find out if Exubera is the right treatment for individual patients. Once a patient starts treatment, it is recommended that a health care provider check lung function again at six months and yearly thereafter.

As with all forms of Insulin, a possible side effect of Exubera is hypoglycemia.

Some patients have reported a mild cough while taking Exubera, which occurred within seconds to minutes after Exubera inhalation. Coughing occurred less frequently as patients continued to use Exubera.

In clinical trials, mean treatment group differences between Exubera and comparator showed that Exubera was associated with small, non-progressive declines in lung function relative to comparator treatments.

Source: Pfizer, 2006
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With:News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page